High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

doi:10.7150/jca.18197

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/31686

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31686

Title:	High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
Authors:	Tian, Yu-Feng Hsieh, Pei-Ling Lin, Ching-Yih Sun, Ding-Ping Sheu, Ming-Jen Yang, Ching-Chieh Lin, Li-Ching He, Hong-Lin Solorzano, Julia Li, Chien-Feng Chang, I-Wei
Contributors:	Chi Mei Med Ctr, Dept Surg, Div Gen Surg Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Chi Mei Med Ctr, Dept Med Image Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Dept Radiat Oncol I Shou Univ, E DA Hosp, Dept Pathol I Shou Univ, Sch Med Chi Mei Med Ctr, Dept Pathol Natl Hlth Res Inst, Natl Inst Canc Res Southern Taiwan Univ Sci & Technol, Dept Biotechnol Kaohsiung Med Univ, Inst Clin Med
Keywords:	ALDOB Aldolase B CCRT chemoradiotherapy rectal cancer
Date:	2017
Issue Date:	2018-11-30 15:52:52 (UTC+8)
Publisher:	Ivyspring Int Publ
Abstract:	Background: Colorectal cancer is the third most common cancer in both sex worldwide and it is also the fourth most common cause of cancer mortality. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer. By data mining a documented database of rectal cancer transcriptome (GSE35452) from Gene Expression Omnibus, National Center of Biotechnology Information, we recognized that ALDOB was the most significantly up-regulated transcript among those related to glycolysis (GO: 0006096). Hence, we analyzed the clinicopathological correlation and prognostic effect of ALDOB protein (Aldolase B), which encoded by ALDOB gene. Methods: ALDOB immunostain was performed in 172 rectal adenocarcinomas treated with preoperative chemoradiotherapy followed by radical surgery, which were divided into high-and low-expression groups. Furthermore, statistical analyses were examined to correlate the relationship between ALDOB immunoreactivity and important clinical and pathological characteristics, as well as three survival indices: disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS). Results: ALDOB (Aldolase B) over-expression was significantly associated with pre-CCRT and post-CCRT tumor advancement, lymphovascular invasion, perineural invasion and poor response to CCRT (all P <= .023). In addition, ALDOB high expression was linked to adverse DSS, LRFS and MeFS in univariate analysis (P <= .0075) and also served as an independent prognosticator indicating dismal DSS and MeFS in multivariate analysis (hazard ratio (HR) = 3.462, 95% confidence interval (CI): 1.263-9.495; HR = 2.846, 95% CI: 1.190-6.808, respectively). Conclusion: ALDOB (Aldolase B) may play an imperative role in rectal cancer progression and responsiveness to neoadjuvant CCRT, and serve as a novel prognostic biomarker. Additional researches to clarify the molecular and biochemical pathways are essential for developing promising ALDOB-targeted therapies for patients with rectal cancers.
Relation:	Journal of Cancer, v.8, n.7, pp.1197-1204
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles [Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1530	View/Open
jca.18197.pdf		845Kb	Adobe PDF	0	View/Open

Loading...